Article
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
British journal of haematology - 1 Aug 2022
Adès Lionel, Duployez Nicolas, Guerci-Bresler Agnes, Laribi Kamel, Peterlin Pierre, Vey Norbert, Thepot Sylvain, Wickenhauser Stefan, Zerazhi Hacene, Stamatoullas Aspassia, Wattel Eric, Recher Christian, Toma Andrea, Dimicoli-Salazar Sophie, Braun Thorsten, Beyne-Rauzy Odile, Marolleau Jean-Pierre, Cheze Stéphane, Park Sophie, Cluzeau Thomas, Nimubona Stanislas, Bordessoule Dominique, Benramdane Riad, Quesnel Bruno, Amé Shanti, de Botton Stéphane, Chermat Fathia, Preudhomme Claude, Chevret Sylvie, Fenaux Pierre
Abstract excerpt
In order to improve the outcome observed with azacitidine (AZA) in higher-risk Myelodysplastic syndrome (MDS), its combination with other drugs in MDS must be evaluated. So far, no combination has not been shown to be more effective than AZA alone. AZA-PLUS was a phase II trial that, in a "pick a winner" approach, randomly assigned patients with higher-risk MDS, CMML and low blast count AML to: AZA; AZA plus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.